Results 31 to 40 of about 380,241 (288)

Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer [PDF]

open access: yesPrecision and Future Medicine, 2017
Metastatic gastric cancer (GC) with limited therapeutic options has a poor prognosis, and therefore, major therapeutic advances are needed. Comprehensive genomic characterization has improved understanding of GC but a great majority of genomic profiling ...
Jang Ho Cho, Jeeyun Lee
doaj   +1 more source

A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma

open access: yesActa Dermato-Venereologica, 2022
Erythroderma is challenging to diagnose. The aim of this single-centre retrospective study was to identify factors that can be used to improve the diagnosis of erythroderma.
Camille Luherne   +10 more
doaj   +1 more source

Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies

open access: yesCancer Cell International, 2021
After being stagnant for decades, there has finally been a paradigm shift in the treatment of cancer with the emergence and application of immune checkpoint inhibitors (ICIs).
Wenwen Yang   +7 more
doaj   +1 more source

Analysis of the Correlation between Molecular Structural Differences of PD-1/PD-L1 Inhibitors and Adverse Events

open access: yesChinese Journal of Lung Cancer, 2020
As a new method, immunotherapy which is targeting programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) plays a more and more important role in the treatment of malignant tumors.
Tongji XIE, Shouzheng WANG, Puyuan XING
doaj   +1 more source

Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy. [PDF]

open access: yesGenes (Basel)
The ability to undergo neoangiogenesis is a common feature with all cancers. Signaling related to vascular endothelial growth factors (VEGF) and their receptors (VEGFR) plays a key role in the process of tumor neoangiogenesis. A close relationship has been demonstrated between excessive VEGF levels and the induction of immunosuppression in the tumor ...
Stachyra-Strawa P   +4 more
europepmc   +4 more sources

Diversification of a protein kinase cascade: IME-2 is involved in nonself recognition and programmed cell death in Neurospora crassa. [PDF]

open access: yes, 2012
Kinase cascades and the modification of proteins by phosphorylation are major mechanisms for cell signaling and communication, and evolution of these signaling pathways can contribute to new developmental or environmental response pathways.
Bueche, Joanna A   +2 more
core   +2 more sources

Programmed cell death protein 1/programmed death ligand-1 checkpoint blockade meets patient-derived organoids [PDF]

open access: yesAnnals of Translational Medicine, 2019
Tumor immunotherapy, particularly programmed cell death protein 1 (PD-1)/programmed death ligand-1 (PD-L1) immune checkpoint blockade, has been instrumental in the successful treatment of cancer. Anti-PD-1/PD-L1 immunotherapy has been approved for many types of cancer (1,2); however, it is generally understood that only a fraction of cancer patients ...
Lejia, Sun, Huayu, Yang, Yilei, Mao
openaire   +2 more sources

Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. [PDF]

open access: yes, 2016
BackgroundMalignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma with few treatment options. Tumor immune state has not been characterized in MPNST, and is important in determining response to immune checkpoint blockade.
Bernthal, Nicholas   +11 more
core   +2 more sources

Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer

open access: yesChinese Journal of Cancer Research, 2022
Triple-negative breast cancer (TNBC) has the worst prognosis among all molecular types of breast cancer. Because of the strong immunogenicity of TNBC cells, programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors, two kinds of immune checkpoint blockade agents, might help improve the prognosis of TNBC. However, how to better use PD-1/PD-L1
Liang, Yuehua   +3 more
openaire   +2 more sources

Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells [PDF]

open access: yes, 2012
For a long time necrosis was thought to be an uncontrolled process but evidences recently have revealed that necrosis can also occur in a regulated manner.
Barna, Gabor   +6 more
core   +6 more sources

Home - About - Disclaimer - Privacy